{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"-Incidence and severity of chronic GVHD will be assessed based on the Seattle criteria","groups":[{"description":"* Day 1: Mobilization with 240 mcg/kg SC AMD3100 and leukopheresis\n* If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3.","id":"OG000","title":"Subcutaneous (SC) Treatment Plan - Donor"},{"description":"* Conditioning Regimen\n\n  * Cyclophosphamide 60mg/kg/day on Days -3 and -2\n  * TBI 550cGy on Day -1\n* GVHD prophylaxis\n\n  \\*Cyclosporin 3.0mg/kg/day beginning on Day -1 then tapered through Day +100\n* PBSC transplant on Day 0","id":"OG001","title":"Recipients"},{"description":"* Day -3: Mobilization with 80-480 mcg/kg/day IV AMD3100 and PK analysis\n* Day 1: Mobilization with 240 mcg/kg/day SC AMD3100 and leukopheresis\n* If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3.","id":"OG002","title":"Intravenous (IV) Treatment Plan - Donor"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only 28 recipients received stem cell products on study. The others were not eligible due to relapse/progression, poor donor collection, receiving non-AMD3100 mobilized cells, or death before day +100.","reportingStatus":"POSTED","timeFrame":"Between Day +100 and +365 post-transplant","title":"Proportion of Recipients Who Experience Chronic GVHD (Recipient Only)","type":"SECONDARY","unitOfMeasure":"Participants"}